# BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis

> **NCT00001789** · PHASE2 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 20 (—)

## Conditions studied

- Glomerulonephritis, Membranoproliferative
- Lupus Nephritis

## Interventions

- **DRUG:** BG9588

## Key facts

- **NCT ID:** NCT00001789
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** —
- **Final completion:** 2000-05
- **Target enrollment:** 20 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001789, "BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*